Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharma (NQ: COLL )

32.74 +0.38 (+1.17%)
Streaming Delayed Price Updated: 11:53 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,544
Open 32.65
Bid (Size) 32.70 (4)
Ask (Size) 32.78 (2)
Prev. Close 32.36
Today's Range 32.48 - 32.99
52wk Range 20.95 - 40.95
Shares Outstanding 32,715,322
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:COLL is an undervalued gem with solid fundamentals.
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily

Performance

YTD
+4.84%
+4.84%
1 Month
+3.35%
+3.35%
3 Month
-5.76%
-5.76%
6 Month
-2.30%
-2.30%
1 Year
+44.87%
+44.87%

More News

Read More
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Via Benzinga
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Via Benzinga
Collegium to Participate in Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Where Collegium Pharmaceutical Stands With Analysts
Via Benzinga
Recap: Collegium Pharmaceutical Q4 Earnings
Via Benzinga
Analyst Expectations For Collegium Pharmaceutical's Future
Via Benzinga
Collegium Reports First Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces CEO Transition
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Why Collegium Pharmaceutical Shares Are Gaining Today
Via Benzinga
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Collegium Provides 2024 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.